Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...

The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high ...

The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...

All the evidence gathered from the five-year trial will be used to demonstrate the long-term effect of weight loss medication ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence ...

Eli Lilly And Co. (NYSE:LLY) is ramping up its legal campaign against the compounding companies temporarily allowed to make ...

Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...